DEBRA Research and Nonsense Therapeutics Form ReadOn Therapeutics

DEBRA Research gGmbH and Nonsense Therapeutics have announced the creation of ReadOn Therapeutics, a non-profit entity focused on therapies for Epidermolysis Bullosa (EB), especially Dystrophic EB. This alliance combines patient advocacy with biotech to transition promising scientific discoveries through crucial development stages, aimed at reducing risks before clinical trials.

Managing Director Alex Hersham, motivated by personal experience as a parent of a child with dystrophic EB, underscores the urgency of innovative treatments. The new company will initially target nonsense mutations affecting type VII collagen, with broader applications potentially impacting other genetic conditions.

ReadOn's unique business model evaluates multiple therapeutic approaches simultaneously, allowing rapid progress to clinical trials and presenting opportunities for collaborations with venture capital and pharma industries. The approach may serve as a template for driving innovation in addressing rare diseases.